Search

Displaying results 3451 - 3460 of 10000 in total
  1. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    the liver have been implicated in its pathogenesis[A32119]. … Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in

  2. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively.

  3. Drug

    Niflumic acid

    go.drugbank.com/drugs/DB04552
    Investigational

    Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

  4. Drug

    Capreomycin

    go.drugbank.com/drugs/DB00314
    ApprovedInvestigational

    Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.

  5. Drug

    R343

    go.drugbank.com/drugs/DB06316
    Investigational

    R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

    Synonyms: 2- {3- [4-(2,2-Difluoro-3 -oxo-3,4-dihydro-2H-benzo [1,4] oxazin-6-ylamino)5-fluoro-pyrimidin-2-ylamino]phenoxy}N-methyl-acetamide
  6. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load. … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection.

  7. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today. … ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.

    Synonyms: N-Desmethylclozapine
  8. Drug

    Rebamipide

    go.drugbank.com/drugs/DB11656
    ApprovedInvestigational

    Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance. … Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate.

  10. Drug

    Etifoxine

    go.drugbank.com/drugs/DB08986
    ApprovedWithdrawn

    Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s. It is used in anxiety disorders and to promote peripheral nerve healing. … It is more effective than lorazepam as an anxiolytic, and has fewer side effects. Etifoxine has been associated with acute liver injury.